Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2017 June-December;19(2-4) > Esperienze Dermatologiche 2017 June-December;19(2-4):47-52

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

ESPERIENZE DERMATOLOGICHE

A Journal on Dermatology


Journal of Istituto Dermatologico San Gallicano
Official Journal of the Associazione Dermatologi Ospedalieri Italiani - A.D.O.I.
Indexed/Abstracted in: EMBASE, Scopus

 

REVIEW  


Esperienze Dermatologiche 2017 June-December;19(2-4):47-52

DOI: 10.23736/S1128-9155.17.00451-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Mometasone furoate and tacalcitol in the treatment of psoriasis: an expert view

Paolo GISONDI

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy


PDF  


Topical corticosteroids have always been considered the first-line treatment for inflammatory diseases of the skin, such as psoriasis. In this setting, the combination of corticosteroids with D3 analogues is also recommended by current guidelines. In this review, we discuss the role of mometasone furoate, a corticosteroid, and tacalcitol, a synthetic vitamin D3 analog, also in a potentially-effective sequential therapy for mild-to-moderate psoriasis. This approach could represent a suitable treatment strategy for psoriatic patients who need a prompt relief of symptoms with no or limited side effects.


KEY WORDS: Mometasone furoate - Psoriasis - 1 Alpha,24-dihydroxyvitamin D3

top of page

Publication History

Issue published online: February 20, 2018
Manuscript accepted: September 1, 2017
Manuscript received: July 28, 2017

Cite this article as

Gisondi P. Mometasone furoate and tacalcitol in the treatment of psoriasis: an expert view. Esperienze Dermatol 2017;19:47-52. DOI: 10.23736/S1128-9155.17.00451-4

Corresponding author e-mail

paolo.gisondi@univr.it